CAP-100
Based on 1 Customer Validation
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.84%
- Masse moléculaire:146.48 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human IgG1 kappa
Human
CCR7/CD197
CAP-100 (0.1-10 ng/μL) demonstrates the most potent binding to CCR7 immunogen SYM1899 (100 ng) with a EC50 of 1.78 ng/mL[1].
CAP-100 (0.01-100 μg/mL) shows dose-dependent inhibition of ligand-induced activation, reaching maximal inhibitions close to 100% in CCR7+ CHO-K1 cells stimulated with CCL19[1].
CAP-100 (0.1-100 μg/mL) binds to CCR7+ non-tumor PB or BM cells from healthy donors at high experimental concentrations[1].
CAP-100 (1-100 μg/mL) impairs the increase of D-actin upon CCL19/CCL21 stimulation in CLL cells[1].
CAP-100 (0.1-100 μg/mL, 4 h) demonstrates a strong dose-related inhibitory activity against CCR7-driven T-PLL cells migration towards 1 μg/mL of CCL19 or CCL21[1].
CAP-100 (10 μg/mL) impairs CCR7-induced migration of CCL cells in trans-endothelial migration (TEM) assays[1].
CAP-100 (10-100 μg/mL, 24 h) does not mediate direct specific-induced cell death but impairs the viability of CCR7-mediated cells which is the protective function in CLL[1].
CAP-100 (10 μg/mL) activated human NK-92-CD16+ cells to induce a strong ADCC on target CLL cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
CAP-100 (25-200 μg/mouse, i.v., one single dose) shows prolonged median overall survival regardless of dose and reduces tumor burden as well as reducing lymph node infiltration in Granta-519-luc+-bearing mice[1].
CAP-100 (10-200 μg/mouse, i.v., one single dose) significantly extends the lifespan of JVM-3-bearing SCID mice compared to Trastuzumab (HY-P9907) (200 μg)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CCR7 (red) with CAP-100 (HY-P991224). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 146.48 kDa
-
Color Colorless to light yellow
-
SMILES
[CAP-100]
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz